PIPELINE

PIPELINE

Apaxen has a pipeline of products at discovery and preclinical stages of development for the treatment of diseases associated with chronic inflammation that depend on NLRP3 Inflammasome activation and MIF. Pulmonary arterial hypertension (PAH) is the primarily targeted indication.

Apaxen has currently three R&D programs:

  • MFC-1040 for the treatment of PAH
  • MFC-1040 for the treatment of pulmonary hypertension secondary to idiopathic pulmonary fibrosis (PH-IPF)
  • APX-Next Generation for treatment of diseases that depend on NLRP3 Inflammasome activity
Apaxen-Pipeline